SIGi001-A-12 Bi-Allelic MAPT HA-tag #U28-12-P29-5

General

Cell Line

hPSCreg name SIGi001-A-18
Cite as:
SIGi001-A-18
Alternative name(s)
SIGi001-A-12 Bi-Allelic MAPT HA-tag #U28-12-P29-5
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
SIGi001-A
(IPSC0028 parental, SAMEA4447455)
SIGi001-A-1
(iPSC0028 SLC17A7/GFP E3)
SIGi001-A-2
(iPSC0028 SLC17A7/GFP C3)
SIGi001-A-3
(iPSC0028 MAPT P301L C4)
SIGi001-A-4
(iPSC0028 MAPT P301L D4)
SIGi001-A-5
(iPSC0028 MAPT P301S 1C9C4)
SIGi001-A-6
(iPSC0028 MAPT P301S 1B9C9)
SIGi001-A-7
(iPSC0028 MAPT P301S 2G2B7)
SIGi001-A-8
(iPSC0028 MAPT P301S+Ex10+16/Clone 7D11A7)
SIGi001-A-9
(iPSC0028 MAPT P301S+Ex10+16/Clone 7H6A1)
SIGi001-A-10
(iPSC0028 MAPT P301S+Ex10+16/Clone 7G4A8)
SIGi001-A-11
(iPSC0028 MAPT P301S+Ex10+16/Clone 7C6A4, SAMEA4451118)
SIGi001-A-21
(SIGi001-AAVS1-FRT)
SIGi001-A-22
(SIGi001-ICAM1-GFP)
SIGi001-A-23
(SIGi001-HC3x)
SIGi001-A-24
(SIGi001-HC3x-ICAM1-GFP)
SIGi001-A-12
(iPSC0028 - BiAllelic MAPT_Ex10+16T/Clone 1F5-D12, SAMEA104237570)
SIGi001-A-13
(iPSC0028 – MonoAllelic MAPT_Ex10+16T/Clone 1D01-11)
SIGi001-A-14
(SIGi001-A Bi-Allelic MAPT HA-tag)
SIGi001-A-15
(SIGi001-A Dox inducible NGN2)
SIGi001-A-16
(SIGi001-A-9 Bi-Allelic MAPT HA-tag)
SIGi001-A-17
(SIGi001-A-9 Dox inducible NGN2)
SIGi001-A-19
(SIGi001-A-12 Dox inducible NGN2)
Last update 19th June 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Bioneer (BION)
Owner Bioneer (BION)
Distributors
Derivation country Denmark

External Databases

BioSamples SAMEA6080817

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information

Sex female
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Family history no
Is the medical history available upon request? no
Is clinical information available? no

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA4447434

Ethics

Also have a look at the ethics information for the parental line SIGi001-A .
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

The source cell information can be found in the parental cell line SIGi001-A.

Reprogramming method

Vector type Integrating
Vector Virus (Retrovirus)
Is the used vector excisable?
No
Absence of reprogramming vector(s)?
No
Reprogramming vectors silenced?
Unknown
Methods used
RT-PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzymatically
Accutase
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative

Genotyping

Karyotyping (Cell Line)

Other Genotyping (Cell Line)

Genetic Modification

Genetic modifications not related to a disease
Isogenic modification
17
NM_001203252
Homozygous
an HA-tag has been added to the endogenous MAPT gene
an HA-tag has been added to the endogenous MAPT gene